Zobrazeno 1 - 10
of 77
pro vyhledávání: '"Aafke H. Honkoop"'
Autor:
Sonja Vliek, Florentine S. Hilbers, Erik van Werkhoven, Ingrid Mandjes, Rob Kessels, Sieta Kleiterp, Esther H. Lips, Lennart Mulder, Mutamba T. Kayembe, Claudette E. Loo, Nicola S. Russell, Marie-Jeanne T. F. D. Vrancken Peeters, Marjo J. Holtkamp, Margaret Schot, Joke W. Baars, Aafke H. Honkoop, Annelie J. E. Vulink, Alex L. T. Imholz, Suzan Vrijaldenhoven, Franchette W. P. J. van den Berkmortel, Jetske M. Meerum Terwogt, Jolanda G. Schrama, Philomeen Kuijer, Judith R. Kroep, Annemieke van der Padt-Pruijsten, Jelle Wesseling, Gabe S. Sonke, Kenneth G. A. Gilhuijs, Agnes Jager, Petra Nederlof, Sabine C. Linn
Publikováno v:
npj Breast Cancer, Vol 9, Iss 1, Pp 1-9 (2023)
Abstract Exploratory analyses of high-dose alkylating chemotherapy trials have suggested that BRCA1 or BRCA2-pathway altered (BRCA-altered) breast cancer might be particularly sensitive to this type of treatment. In this study, patients with BRCA-alt
Externí odkaz:
https://doaj.org/article/8df2c3c9b54e4fdaa94ca1a2ca82efc6
Autor:
Vivianne C.G. Tjan-Heijnen, Senna W.M. Lammers, Sandra M.E. Geurts, Ingeborg J.H. Vriens, Astrid C.P. Swinkels, Carolien H. Smorenburg, Maurice J.C. van der Sangen, Judith R. Kroep, Hiltje de Graaf, Aafke H. Honkoop, Frans L.G. Erdkamp, Wilfred K. de Roos, Sabine C. Linn, Alexander L.T. Imholz
Publikováno v:
EClinicalMedicine, Vol 58, Iss , Pp 101901- (2023)
Summary: Background: The DATA study evaluated the use of two different durations of anastrozole in patients with hormone receptor-positive breast cancer who were disease-free after 2–3 years of tamoxifen. We hereby present the follow-up analysis, w
Externí odkaz:
https://doaj.org/article/5623c66d14bc4b84bad476914391d5ba
Autor:
Anouk H. Eijkelboom, Linda de Munck, Marie-Jeanne T. F. D. Vrancken Peeters, Mireille J. M. Broeders, Luc J. A. Strobbe, Monique E. M. M. Bos, Marjanka K. Schmidt, Cristina Guerrero Paez, Marjolein L. Smidt, Maud Bessems, Janneke Verloop, Sabine Linn, Marc B. I. Lobbes, Aafke H. Honkoop, Desirée H. J. G. van den Bongard, Pieter J. Westenend, Jelle Wesseling, C. Willemien Menke-van der Houven van Oordt, Vivianne C. G. Tjan-Heijnen, Sabine Siesling, the NABON COVID-19 Consortium and the COVID and Cancer-NL Consortium
Publikováno v:
Journal of Hematology & Oncology, Vol 14, Iss 1, Pp 1-12 (2021)
Abstract Background The onset of the COVID-19 pandemic forced the Dutch national screening program to a halt and increased the burden on health care services, necessitating the introduction of specific breast cancer treatment recommendations from wee
Externí odkaz:
https://doaj.org/article/a57c6e3e85634fe69dad8387aa9a8708
Autor:
Jeroen W.G. Derksen, Sophie A. Kurk, Petra H.M. Peeters, Bram Dorresteijn, Marion Jourdan, Ankie M.T. van derVelden, Peter Nieboer, Robert S. deJong, Aafke H. Honkoop, Cornelis J.A. Punt, Miriam Koopman, Anne M. May
Publikováno v:
Journal of Cachexia, Sarcopenia and Muscle, Vol 11, Iss 4, Pp 919-928 (2020)
Abstract Background Skeletal muscle mass (SMM) loss is common in metastatic colorectal cancer (mCRC) patients and associated with poor clinical outcomes, including increased treatment‐related toxicities and reduced survival. Muscle loss may contrib
Externí odkaz:
https://doaj.org/article/58f882ec34e24402b6d47894a4ed50df
Autor:
Epie Boven, Harm van Tinteren, Aafke H. Honkoop, Johanneke E.A. Portielje, Ankie M.T. van der Velden, Joan van den Bosch, Monique M.E.M. Bos, Agnes Jager, Nienke M. Nota, Siu W. Lam
Purpose: We examined whether pretreatment levels of angiogenesis- or hypoxia-related proteins and their changes after one cycle of first-line bevacizumab-based therapy were associated with response, PFS, or OS in patients with metastatic breast cance
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7ba4f07774af27b81ffc97bcaf6441ec
https://doi.org/10.1158/1078-0432.c.6524210.v1
https://doi.org/10.1158/1078-0432.c.6524210.v1
Autor:
Epie Boven, Harm van Tinteren, Aafke H. Honkoop, Johanneke E.A. Portielje, Ankie M.T. van der Velden, Joan van den Bosch, Monique M.E.M. Bos, Agnes Jager, Nienke M. Nota, Siu W. Lam
Supplementary Table 1. Clinical outcome of original trial population and biomarker population Supplementary Table 2. Baseline plasma protein levels vs baseline patient and tumor characteristics Supplementary Table 3. Spearman Rho correlation coeffici
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::92209ee6113aed3e189e26a6148dad36
https://doi.org/10.1158/1078-0432.22459391
https://doi.org/10.1158/1078-0432.22459391
Autor:
Pim J. French, Johan M. Kros, Peter A.E. Sillevis Smitt, René M. Vernhout, Bronno van der Holt, Aafke H. Honkoop, Jan Buter, Monique C.J. Hanse, Laurens V. Beerepoot, Annemiek Walenkamp, Hendrika M. Oosterkamp, Walter Taal, Maurice de Wit, Ya Gao, René Böttcher, Peter van der Spek, Andrew Stubbs, Hina Naz-Khan, Youri Hoogstrate, Martin J. van den Bent, Lale Erdem-Eraslan
Mutations segregate in distinct molecular subtypes.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2a36b6f197483cbc756075c5f698cbd8
https://doi.org/10.1158/0008-5472.22408541.v1
https://doi.org/10.1158/0008-5472.22408541.v1
Autor:
Pim J. French, Johan M. Kros, Peter A.E. Sillevis Smitt, René M. Vernhout, Bronno van der Holt, Aafke H. Honkoop, Jan Buter, Monique C.J. Hanse, Laurens V. Beerepoot, Annemiek Walenkamp, Hendrika M. Oosterkamp, Walter Taal, Maurice de Wit, Ya Gao, René Böttcher, Peter van der Spek, Andrew Stubbs, Hina Naz-Khan, Youri Hoogstrate, Martin J. van den Bent, Lale Erdem-Eraslan
Reclassification of Phillips dataset primary v recurrent samples.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::90d9ad032405a97ca3b399d1ac4c9e80
https://doi.org/10.1158/0008-5472.22408505.v1
https://doi.org/10.1158/0008-5472.22408505.v1
Autor:
Pim J. French, Johan M. Kros, Peter A.E. Sillevis Smitt, René M. Vernhout, Bronno van der Holt, Aafke H. Honkoop, Jan Buter, Monique C.J. Hanse, Laurens V. Beerepoot, Annemiek Walenkamp, Hendrika M. Oosterkamp, Walter Taal, Maurice de Wit, Ya Gao, René Böttcher, Peter van der Spek, Andrew Stubbs, Hina Naz-Khan, Youri Hoogstrate, Martin J. van den Bent, Lale Erdem-Eraslan
The results from the randomized phase II BELOB trial provided evidence for a potential benefit of bevacizumab (beva), a humanized monoclonal antibody against circulating VEGF-A, when added to CCNU chemotherapy in patients with recurrent glioblastoma
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a25cac1b80eba75c11040b651d6e1271
https://doi.org/10.1158/0008-5472.c.6507551.v1
https://doi.org/10.1158/0008-5472.c.6507551.v1
Autor:
Pim J. French, Johan M. Kros, Peter A.E. Sillevis Smitt, René M. Vernhout, Bronno van der Holt, Aafke H. Honkoop, Jan Buter, Monique C.J. Hanse, Laurens V. Beerepoot, Annemiek Walenkamp, Hendrika M. Oosterkamp, Walter Taal, Maurice de Wit, Ya Gao, René Böttcher, Peter van der Spek, Andrew Stubbs, Hina Naz-Khan, Youri Hoogstrate, Martin J. van den Bent, Lale Erdem-Eraslan
Legends for Supplementary Figures S1-S13.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5f1c44f2f9184d5d626b2b8a51d54fdd
https://doi.org/10.1158/0008-5472.22408571.v1
https://doi.org/10.1158/0008-5472.22408571.v1